午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ShangHai Biochempartner Co.,Ltd??? ?? ??? ?????.

?? ?:ShangHai Biochempartner Co.,Ltd
??:177-54423994
???:2853530910@QQ.com
??:China
URL: www.biochempartner.com
? ?? ?:7990
65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80

?? ????

Flotetuzumab1664355-28-5
OTX 008286936-40-1C52H72N8O8
1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione1380532-27-3C10H11F3N2O5
YM150365462-23-3C27H30N4O4
SBI-4251451272-71-1C13H12ClN3O4S
Ro60-0175169675-08-5C11H12ClFN2
2,4-Imidazolidinedione, 5-[3-[[4-[(3-methylphenyl)methoxy]phenyl]thio]-2-furanyl]-877176-23-3C21H18N2O4S
MRTX17192630904-45-7C23H18ClFN6O2
Sigma-1 receptor antagonist 21639220-15-7C20H26ClN3O2
GSK2512125968-05-8C29H37FN6O4S
Erucin???4430-36-8C6H11NS2
Ensitrelvir fumarate2757470-18-9C26H21ClF3N9O6
Boc-Val-Ala-PAB-PNP1884578-00-0C27H34N4O9
Tamtuvetmab1608122-71-9
Blontuvetmab1608112-78-2
Tilavonemab2096513-89-0
Olendalizumab1337966-73-0
Garetosmab2097125-54-5
Maftivimab2135632-36-7
Andecaliximab1518996-49-0
ML3392579689-83-9C26H32ClN3O5
Mc-Val-Ala-PAB-PNP1639939-40-4C32H37N5O10
YTX-4652225824-53-1C25H26N6O3
Varisacumab1610010-60-0
Istiratumab1509928-04-4
Bermekimab1401965-15-8
Pepinemab2097151-87-4
Indusatumab1497400-26-6
Satralizumab1535963-91-7
Cabiralizumab1613144-80-1
Xentuzumab1417158-65-6
Refanezumab1233953-61-1
Mirvetuximab1453084-36-0
Bocidelpar2095128-20-2C25H27F3N2O3
Tisotumab1418628-81-5
Brazikumab1610353-18-8
Crizanlizumab1690318-25-2
Camrelizumab1798286-48-2
Ranevetmab1632282-27-9
Vunakizumab1792181-33-9
Depatuxizumab1471999-69-5
Utomilumab1417318-27-4
Telisotuzumab1781223-80-0
Aprutumab1634620-63-5
Elezanumab1791416-49-3
Lutikizumab1791411-57-8
Eptinezumab1644539-04-7
Fremanezumab1655501-53-3
Dezamizumab1662664-56-3
Birtamimab1608108-91-3
Setrusumab1847394-95-9
Rozanolixizumab1584645-37-3
Galcanezumab1578199-75-3
Erenumab1582205-90-0
Carotuximab1268714-50-6
Timolumab1073538-99-4
Lanadelumab1426055-14-2
Vonlerolizumab1638935-72-4
Duvortuxizumab1831098-91-9
SR16641338259-05-4C33H29N3O5
RY7851393748-80-5C21H20N4O2S
JYN423461903742-34-6C27H24BrN7O3
GI 181771305366-98-7C34H31N5O6
JQKD-822410512-38-6C27H40N4O5
SCD1 inhibitor-31282606-48-7C19H16FN7O2
Amivantamab2171511-58-1
Bleselumab1453067-91-8
Plozalizumab1610761-46-0
Trevogrumab1429201-24-0
Inebilizumab1299440-37-1
Navivumab1443004-16-7
Obiltoxaximab1351337-07-9
Tomaralimab1449294-76-1
Losatuxizumab1801544-27-3
Rovalpituzumab1613313-01-1
Ifabotuzumab1234137-51-9
Rinucumab1569263-06-4
Opicinumab1422268-07-2
Clivatuzumab Tetraxetan1462876-11-4
Ascrinvacumab1463459-96-2
Monalizumab1228763-95-8
Lilotomab1453362-55-4
Afasevikumab1589503-30-9
Risankizumab1612838-76-2
Indusatumab Vedotin1514889-12-3
(R)-GSK-36850322170140-50-6C22H24N6OS
BioE-11971268863-69-9C20H18FN3O2
INE9632640567-43-5C19H26N6O2S
Suptavumab1629615-23-1
Lupartumab1640971-88-5
Emapalumab1709815-23-5
Enoblituzumab1353485-38-7
Zunsemetinib1640282-42-3C25H22ClF2N5O3
Lacutamab2187368-16-5
1-Piperidinamine, N-hydroxy-N-nitroso-56329-24-9C5H11N3O2
TH54272253744-56-6C20H20Cl2N8O3
AZD-1940881413-29-2C20H29F2N3O2S
Ravulizumab1803171-55-2
SUC-ALA-ALA-PRO-PHE-PNA107409-54-1C30H34N6O8
FTO-IN-32585198-87-2C12H10N4OS
65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
Copyright 2019 ? ChemicalBook. All rights reserved